Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

22 Dec 2012

Abstract excerpt

We report the safety and tolerability of 87 infusions of lentiviral vector–modified autologous CD4 T cells (VRX496-T; trade name, Lexgenleucel-T) in 17 HIV patients with well-controlled viremia. Antiviral effects were studied during analytic treatment interruption in a subset of 13 patients. VRX496-T was associated with a decrease in viral load set points in 6 of 8 subjects (P = .08). In addition, A → G...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cytomegalovirus and herpesvirus research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23264589
DOI: 10.1182/blood-2012-07-447250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIVPMID 23264589Read ↗

Preferential Survival of CD4+ T Lymphocytes Engineered with Anti-Human Immunodeficiency Virus (HIV) Genes in HIV-Infected IndividualsSemantic proximity Read ↗

Clinical efficacy of gene-modified stem cells in adenosine deaminase–deficient immunodeficiencySemantic proximity Read ↗

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsSemantic proximity Read ↗

Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiencySemantic proximity Read ↗

A Controlled, Phase 1 Clinical Trial to Evaluate the Safety and Effects in HIV-1 Infected Humans of Autologous Lymphocytes Transduced with a Ribozyme that Cleaves HIV-1 RNA. University of California San Diego, La Jolla, CaliforniaSemantic proximity Read ↗

Multiple treatment interruptions and protecting HIV-specific CD4 T cells enable durable CD8 T cell response and viral controlSemantic proximity Read ↗

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgeneSemantic proximity Read ↗

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.Semantic proximity Read ↗

Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapySemantic proximity Read ↗

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infectionSemantic proximity Read ↗

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T CellsSemantic proximity Read ↗

Infusion of CCR5 Gene-Edited T Cells Allows Immune Reconstitution, HIV Reservoir Decay, and Long-Term Virological ControlSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.